Literature DB >> 8396012

The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine.

A J Brown1, J Finch, M Grieff, C Ritter, N Kubodera, Y Nishii, E Slatopolsky.   

Abstract

22-Oxacalcitriol (OCT) is one of several new analogs of vitamin D that retain many of the therapeutically useful properties of 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], but have much less calcemic activity. In the present study we examined the actions of OCT on intestinal calcium absorption and calbindin D9k mRNA in vitamin D-deficient rats. After ip injection of OCT (1 microgram/kg), calcium absorption increased significantly by 2 h and was maximal at 4 h (2.5-fold above control), but returned to pretreatment levels by 16 h. In contrast, the same dose of 1,25-(OH)2D3 caused a 3-fold increase in calcium absorption, which lasted more than 48 h. The transient effect of OCT on calcium absorption was also observed when the analog was infused at a dose of 1 micrograms/kg.day for 3 days. At the end of the infusion period, calcium absorption was 3-fold higher than that in vehicle-infused controls, but fell to pretreatment levels by 24 h after removing the minipumps. The time courses for induction of calbindin D9k mRNA were similar for OCT and 1,25-(OH)2D3, with no change observed until more than 4 h after injection. However, calbindin mRNA levels returned to pretreatment values more rapidly in the OCT-treated rats. Consistent with these findings, we observed that a 1 microgram/kg dose of [3H] OCT was completely cleared by 4-6 h after injection. This was paralleled by a loss of [3H]OCT associated with the intestinal vitamin D receptor. The rapid clearance of OCT is probably due to its low affinity for the serum vitamin D-binding protein. This low affinity would also be expected to allow greater accessibility to target cells. In support of this, we found that higher amounts of OCT than 1,25-(OH)2D3 were associated with the intestinal vitamin D receptor after the injection of several doses of these tritiated ligands. In summary, our results indicate that the pharmacokinetic properties of OCT are responsible at least in part for its low calcemic activity. Furthermore, comparison of the transient elevation of calcium absorption by OCT with its more prolonged effects on PTH and calbindin D9k indicates that each action of vitamin D compounds has a distinct biological half-life. The short circulating half-life of OCT can exploit these differences to provide a therapeutic advantage in the treatment of vitamin D-responsive diseases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396012     DOI: 10.1210/endo.133.3.8396012

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.

Authors:  Piergiorgio Bolasco
Journal:  Clin Cases Miner Bone Metab       Date:  2009-09

Review 2.  Vitamin D and its analogs in chronic renal failure.

Authors:  E Slatopolsky; A J Brown
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 3.  Minimizing bone abnormalities in children with renal failure.

Authors:  Helena Ziólkowska
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

4.  Case report: Electron microscopic evaluation of bone from a patient treated with cinacalcet hydrochloride, maxacalcitol, and alfacalcidol for hyperparathyroid bone disease with secondary hyperparathyroidism.

Authors:  A Yajima; K Tsuchiya; L F Bonewald; M Inaba; Y Tominaga; T Tanizawa; A Ito; K Nitta
Journal:  Osteoporos Int       Date:  2018-02-28       Impact factor: 4.507

5.  A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis.

Authors:  K Makibayashi; M Tatematsu; M Hirata; N Fukushima; K Kusano; S Ohashi; H Abe; K Kuze; A Fukatsu; T Kita; T Doi
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

Review 6.  Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease.

Authors:  Mario Cozzolino; Maurizio Gallieni; Sabina Pasho; Giuditta Fallabrino; Paola Ciceri; Elisa Maria Volpi; Laura Olivi; Diego Brancaccio
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 7.  Are new vitamin D analogues in renal bone disease superior to calcitriol?

Authors:  Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2005-02-03       Impact factor: 3.714

Review 8.  Vitamin D metabolism, mechanism of action, and clinical applications.

Authors:  Daniel D Bikle
Journal:  Chem Biol       Date:  2014-02-13

9.  Conformational change and enhanced stabilization of the vitamin D receptor by the 1,25-dihydroxyvitamin D3 analog KH1060.

Authors:  G C van den Bemd; H A Pols; J C Birkenhäger; J P van Leeuwen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

Review 10.  New Vitamin D analogues for osteodystrophy in chronic kidney disease.

Authors:  John Cunningham
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.